192 related articles for article (PubMed ID: 28743369)
21. Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study.
Rose PG; Java JJ; Morgan MA; Alvarez-Secord A; Kesterson JP; Stehman FB; Warshal DP; Creasman WT; Hanjani P; Morris RT; Copeland LJ
Gynecol Oncol; 2016 Dec; 143(3):511-515. PubMed ID: 27692669
[TBL] [Abstract][Full Text] [Related]
22. Pre-operative serum albumin is associated with post-operative complication rate and overall survival in patients with epithelial ovarian cancer undergoing cytoreductive surgery.
Ataseven B; du Bois A; Reinthaller A; Traut A; Heitz F; Aust S; Prader S; Polterauer S; Harter P; Grimm C
Gynecol Oncol; 2015 Sep; 138(3):560-5. PubMed ID: 26163893
[TBL] [Abstract][Full Text] [Related]
23. Does the primary route of spread have a prognostic significance in stage III non-serous epithelial ovarian cancer?
Sahin H; Meydanli MM; Sari ME; Yalcin I; Çoban G; Ozkan NT; Cuylan ZF; Erdem B; Gungorduk K; Akbayir Ö; Dede M; Salman MC; Güngör T; Ayhan A
J Ovarian Res; 2018 Mar; 11(1):21. PubMed ID: 29506569
[TBL] [Abstract][Full Text] [Related]
24. Baseline quality of life and performance status as prognostic factors in patients with extensive-stage disease small cell lung cancer treated with pemetrexed plus carboplatin vs. etoposide plus carboplatin.
Reck M; Thatcher N; Smit EF; Lorigan P; Szutowicz-Zielinska E; Liepa AM; Winfree KB; Peterson P; Guba SC; Socinski MA
Lung Cancer; 2012 Dec; 78(3):276-81. PubMed ID: 23043970
[TBL] [Abstract][Full Text] [Related]
25. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
[TBL] [Abstract][Full Text] [Related]
26. Assessment of factors that contribute to decreased quality of life in Gynecologic Oncology Group ovarian cancer trials.
von Gruenigen VE; Huang HQ; Gil KM; Gibbons HE; Monk BJ; Rose PG; Armstrong DK; Cella D; Wenzel L
Cancer; 2009 Oct; 115(20):4857-64. PubMed ID: 19691091
[TBL] [Abstract][Full Text] [Related]
27. Elevated plasma fibrinogen levels and prognosis of epithelial ovarian cancer: a cohort study and meta-analysis.
Luo Y; Kim HS; Kim M; Lee M; Song YS
J Gynecol Oncol; 2017 May; 28(3):e36. PubMed ID: 28382799
[TBL] [Abstract][Full Text] [Related]
28. A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer.
Suidan RS; St Clair CM; Lee SJ; Barlin JN; Long Roche KC; Tanner EJ; Sonoda Y; Barakat RR; Zivanovic O; Chi DS
Gynecol Oncol; 2014 Sep; 134(3):468-72. PubMed ID: 25042672
[TBL] [Abstract][Full Text] [Related]
29. Role of neutrophil to lymphocyte ratio as a prognostic indicator for epithelial ovarian cancer.
Thavaramara T; Phaloprakarn C; Tangjitgamol S; Manusirivithaya S
J Med Assoc Thai; 2011 Jul; 94(7):871-7. PubMed ID: 21774296
[TBL] [Abstract][Full Text] [Related]
30. Prognostic factors in young ovarian cancer patients: An analysis of four prospective phase III intergroup trials of the AGO Study Group, GINECO and NSGO.
Klar M; Hasenburg A; Hasanov M; Hilpert F; Meier W; Pfisterer J; Pujade-Lauraine E; Herrstedt J; Reuss A; du Bois A
Eur J Cancer; 2016 Oct; 66():114-24. PubMed ID: 27561452
[TBL] [Abstract][Full Text] [Related]
31. Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study.
Horowitz NS; Larry Maxwell G; Miller A; Hamilton CA; Rungruang B; Rodriguez N; Richard SD; Krivak TC; Fowler JM; Mutch DG; Van Le L; Lee RB; Argenta P; Bender D; Tewari KS; Gershenson D; Java JJ; Bookman MA
Gynecol Oncol; 2018 Jan; 148(1):49-55. PubMed ID: 29174555
[TBL] [Abstract][Full Text] [Related]
32. Association between miR-200c and the survival of patients with stage I epithelial ovarian cancer: a retrospective study of two independent tumour tissue collections.
Marchini S; Cavalieri D; Fruscio R; Calura E; Garavaglia D; Fuso Nerini I; Mangioni C; Cattoretti G; Clivio L; Beltrame L; Katsaros D; Scarampi L; Menato G; Perego P; Chiorino G; Buda A; Romualdi C; D'Incalci M
Lancet Oncol; 2011 Mar; 12(3):273-85. PubMed ID: 21345725
[TBL] [Abstract][Full Text] [Related]
33. Dose-dense approaches to ovarian cancer treatment.
Katsumata N
Curr Treat Options Oncol; 2015 May; 16(5):21. PubMed ID: 25859831
[TBL] [Abstract][Full Text] [Related]
34. Prognostic factors for maximally or optimally cytoreduced stage III nonserous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy.
Cuylan ZF; Meydanli MM; Sari ME; Akbayir O; Celik H; Dede M; Sahin H; Gungorduk K; Kuscu E; Ozgul N; Gungor T; Ayhan A
J Obstet Gynaecol Res; 2018 Jul; 44(7):1284-1293. PubMed ID: 29727055
[TBL] [Abstract][Full Text] [Related]
35. Fear of recurrence, emotional well-being and quality of life among long-term advanced ovarian cancer survivors.
Osann K; Wenzel L; McKinney C; Wagner L; Cella D; Fulci G; Scroggins MJ; Lankes HA; Wang V; Nephew KP; Maxwell GL; Mok SC; Conrads TP; Miller A; Birrer M
Gynecol Oncol; 2023 Apr; 171():151-158. PubMed ID: 36905875
[TBL] [Abstract][Full Text] [Related]
36. Association Between Health-Related Quality of Life and Progression-Free Survival in Patients With Advanced Cancer: A Secondary Analysis of SWOG Clinical Trials.
Hui D; Darke AK; Guthrie KA; Subbiah IM; Unger JM; Hershman DL; Krouse RS; Bakitas M; O'Rourke MA
JCO Oncol Pract; 2022 Apr; 18(4):e442-e451. PubMed ID: 34606328
[TBL] [Abstract][Full Text] [Related]
37. Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study.
Deraco M; Virzì S; Iusco DR; Puccio F; Macrì A; Famulari C; Solazzo M; Bonomi S; Grassi A; Baratti D; Kusamura S
BJOG; 2012 Jun; 119(7):800-9. PubMed ID: 22571746
[TBL] [Abstract][Full Text] [Related]
38. The prognostic significance of preoperative leukocytosis in epithelial ovarian carcinoma: a retrospective cohort study.
So KA; Hong JH; Jin HM; Kim JW; Song JY; Lee JK; Lee NW
Gynecol Oncol; 2014 Mar; 132(3):551-5. PubMed ID: 24440470
[TBL] [Abstract][Full Text] [Related]
39. Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.
Skaznik-Wikiel ME; Lesnock JL; McBee WC; Beriwal S; Zorn KK; Richard SD; Krivak TC; Edwards RP
Int J Gynecol Cancer; 2012 Feb; 22(2):232-7. PubMed ID: 22080886
[TBL] [Abstract][Full Text] [Related]
40. Health-related quality of life during and after intraperitoneal versus intravenous chemotherapy for optimally debulked ovarian cancer: a Gynecologic Oncology Group Study.
Wenzel LB; Huang HQ; Armstrong DK; Walker JL; Cella D;
J Clin Oncol; 2007 Feb; 25(4):437-43. PubMed ID: 17264340
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
